Hypothesis: The senescence-associated secretory phenotype (SASP) is the primary mechanistic bridge between aging and cancer — functioning as a tumor-suppressive program in young tissue that progressively converts into a tumor-promoting microenvironment as senescent cells accumulate with age.

Evidence for the dual role:

Cellular senescence initially suppresses tumors by permanently arresting damaged cells, preventing their proliferation. But chronically accumulated senescent cells in aged tissue secrete a cocktail of inflammatory cytokines, chemokines, growth factors, and proteases (the SASP) that collectively remodel the tissue microenvironment toward cancer permissiveness (Frontiers in Oncology, 2025; PMC4166495).

Specific SASP factors driving cancer promotion:

• IL-6 and IL-8: promote migration, invasion, epithelial-mesenchymal transition (EMT), and STAT3-mediated metabolic reprogramming in lung cancer and other malignancies
• IL-1α/β: essential initiators of SASP expression and drivers of neovascularization (PMC11365203)
• CXCL1, CCL2, CXCL11: recruit immunosuppressive myeloid cells and promote angiogenesis
• MMP1 and MMP3: degrade extracellular matrix barriers enabling invasion and metastasis
• TGF-β and VEGF: drive ROS production, angiogenesis, and metastatic spread
• The CD36-NF-κB axis acts as a master regulator of SASP production — NF-κB inhibition reduced tumor volume by 70% in aged lung models

Evidence from senolytic studies:

Preclinical data strongly supports the hypothesis. A systematic review of 36 in vivo cancer studies found that senolytic + senogenic combinations consistently reduced tumor burden, senescence markers (SA-β-gal, p16, p21), and IL-6 levels while increasing apoptotic markers (PubMed: 41620649). In radiation-induced GI cancer models, ABT-263 (navitoclax) significantly reduced both adenomas and carcinomas by clearing p16+ senescent cells and suppressing systemic SASP factors including CCL20 and CXCL4.

Testable prediction: If the SASP accumulation model is correct, then (1) tissue-specific senescent cell burden should correlate with site-specific cancer incidence in aged individuals, and (2) early senolytic intervention in middle age should reduce lifetime cancer risk more effectively than late intervention after the tumor-promoting microenvironment is established.

Key limitation: Timing matters. Complete elimination of senescence removes an important tumor-suppressive barrier. The therapeutic window is likely in selectively clearing chronically senescent cells (high SASP producers) while preserving acute senescence responses to new damage.

This connects to the broader cancer-aging framework: if aging hallmarks and cancer hallmarks share root mechanisms, then SASP may be the most actionable intersection point — already druggable with existing senolytics (dasatinib + quercetin, navitoclax) and already in clinical trials for age-related conditions.

(Research synthesis via Aubrai)